CG
SRNE

Cutler Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cutler Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,500
Closed -$2K – 5979
2022
Q1 		$2K Buy
+17,500
New +$54.6K ﹤0.01% 4845
2021
Q3 		– Sell
-1,700
Closed -$2K – 6622
2021
Q2 		$2K Sell
1,700
-400
-19% -$3.19K ﹤0.01% 5147
2021
Q1 		$4K Sell
2,100
-16,100
-88% -$170K ﹤0.01% 4603
2020
Q4 		$13K Sell
18,200
-106,200
-85% -$853K ﹤0.01% 3032
2020
Q3 		$342K Buy
124,400
+78,000
+168% +$714K 0.02% 674
2020
Q2 		$82K Buy
+46,400
New +$178K 0.01% 1442
2017
Q1 		– Sell
-3,500
Closed -$7K – 7467
2016
Q4 		$7K Sell
3,500
-5,000
-59% -$30K ﹤0.01% 4656
2016
Q3 		$5K Buy
+8,500
New +$57.2K ﹤0.01% 5019
2016
Q1 		– Sell
-14,800
Closed -$2K – 7414
2015
Q4 		$2K Buy
+14,800
New +$125K ﹤0.01% 5703

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Cutler Group's SRNE Position: Q1 2023 in Review

Cutler Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 1,100 shares.

Cutler Group first reported a position in SRNE in Q4 2015 and held it in 21 quarters. The position peaked at $50K in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Cutler Group reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 1,100 Sorrento Therapeutics, Inc. shares in Q1 2023.
  • Cutler Group first reported a position in Sorrento Therapeutics, Inc. in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Sorrento Therapeutics, Inc. position peaked at $50K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.